Alzamend Neuro, Inc.

Equities

ALZN

US02262M4078

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 21:30:00 04/06/2024 BST			5-day change	1st Jan Change
0.58 ^USD	0.00%		+1.22%	-34.83%

05-09	Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding	CI
03-25	Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	CI

Alzamend Neuro, Inc. Announces Appointment of Terri Hunter to Its Scientific Advisory Board

April 04, 2022 at 01:00 pm

Alzamend Neuro, Inc. announced the appointment of Dr. Terri Hunter, Ph.D., a Technology Transfer Specialist, to its Scientific Advisory Board. During her tenure at the University of South Florida (“USF”), Dr. Hunter was responsible for managing the patent portfolio associated with Alzamend's two product candidates, AL001 and AL002.

Latest news about Alzamend Neuro, Inc.

Alzamend Neuro, Inc. announced that it expects to receive $25 million in funding	05-08	CI
Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2024	03-25	CI
Alzamend Neuro, Inc. announced that it expects to receive $6 million in funding from Ault Lending, LLC	01-30	CI
Alzamend Neuro, Inc. Appoints Milton C. Ault, III as a Director and Vice Chairman	01-05	CI
Alzamend Neuro, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended October 31, 2023	12-15	CI
Alzamend Neuro, Inc. Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Post-Traumatic Stress Disorder Patients	12-11	CI
Alzamend Neuro Receives FDA Approval to Proceed With Phase 2A Study of AL001 Depression Treatment Candidate	11-20	MT
Alzamend Neuro Gets FDA Approval for Trial of Depression Treatment	11-20	DJ
Alzamend Neuro Receives FDA " Study May Proceed" Notification for A Phase IIA Clinical Trial of Al001, A Next-Generation Lithium Therapeutic Drug Candidate, in Major Depressive Disorder Patients	11-20	CI
Alzamend Neuro, Inc. Submits IND Application for A Phase IIa Clinical Trial in Post-Traumatic Stress Disorder Patients of Next-Generation Lithium Therapeutic Drug Candidate AL001	11-13	CI
Wall Street Set to Open Higher Monday as Investors Parse Earnings, Await Fed Meeting	30/10/23	MT
Alzamend Neuro Seeks FDA Nod to Start Trial in Major Depressive Disorder	23/10/23	MT
Alzamend Neuro, Inc. Submits Investigational New Drug Application for A Phase IIA Clinical Trial in Major Depressive Disorder Patients of Its Next-Generation Lithium Therapeutic Drug Candidate AL001	23/10/23	CI
Alzamend Neuro, Inc Receives FDA ?Study May Proceed? Notification for a Phase IIA Clinical Trial of AL001, a Next-Generation Lithium Therapeutic Drug Candidate, in Bipolar Disorder Patients	02/10/23	CI
Alzamend Neuro Secures Extension to Regain Compliance With Nasdaq's Minimum Bid Price Rule	25/09/23	MT
Alzamend Neuro, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2023	13/09/23	CI
Alzamend Neuro Files New Drug Application With FDA to Begin Bipolar Disorder Study of Investigational Therapy AL001	30/08/23	MT
Alzamend Neuro, Inc. Reports Earnings Results for the Full Year Ended April 30, 2023	27/07/23	CI
Alzamend N Neuro, Inc. Announces Positive Phase IIA Clinical Trial Results for AL001	22/06/23	CI
Maxim Initiates Alzamend Neuro at Buy With $1.50 Price Target	12/04/23	MT
Alzamend Neuro Launches Phase 1/2a Trial of Vaccine Candidate to Treat Dementia Linked to Alzheimer's	03/04/23	MT
Alzamend Neuro, Inc Announces the Initiation of A Phase I/Iia Trial for Its Immunotherapy Vaccine to Treat Mild to Moderate Dementia of the Alzheimer’S Type	03/04/23	CI
Alzamend Neuro, Inc. Announces Completion of Clinical Portion of Phase IIA Multiple Ascending Dose Clinical Trial for AL001 Treatment of Dementia Related to Alzheimer's	22/03/23	CI
Alzamend Neuro, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended January 31, 2023	15/03/23	CI
Top Premarket Decliners	06/03/23	MT

Chart Alzamend Neuro, Inc.

Duration

Period

More charts

Company Profile

Alzamend Neuro, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing novel products for the treatment of Alzheimer's disease (Alzheimer's), bipolar disorder (BD), major depressive disorder (MDD) and post-traumatic stress disorder (PTSD). The Company's pipeline consists of two novel therapeutic drug candidates: AL001, and ALZN002. AL001 is a patented ionic cocrystal technology delivering a therapeutic combination of lithium, salicylate and proline through three royalty-bearing exclusive worldwide licenses from the University of South Florida Research Foundation, Inc., (the Licensor). AL001 is used for Alzheimer's, BD, MDD and PTSD treatment. ALZN002 is a patented method using a mutant peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patientâs immunological system to combat Alzheimer's through a royalty-bearing exclusive worldwide license from the Licensor.

Sector

Biotechnology & Medical Research

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

0.58 USD

Average target price

21 USD

Spread / Average Target

+3,520.69%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ALZAMEND NEURO, INC.	-34.83%	4.28M
MODERNA, INC.	+46.19%	55.7B
LONZA GROUP AG	+40.06%	39.91B
IQVIA HOLDINGS INC.	-6.14%	39.57B
CELLTRION, INC.	-6.65%	28.16B
ICON PUBLIC LIMITED COMPANY	+12.33%	26.3B
ALNYLAM PHARMACEUTICALS, INC.	-21.78%	18.94B
MEDPACE HOLDINGS, INC.	+28.38%	12.17B
UNITED THERAPEUTICS CORPORATION	+24.18%	12.12B
BIO-TECHNE CORPORATION	-0.35%	12.12B

Other Biotechnology & Medical Research